



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

7

Complete if Known

Application Number

10/777,820

Filing Date

February 12, 2004

First Named Inventor

Collins *et al.*

Group Art Unit

Unassigned

1654

Examiner

Unassigned

Attorney Docket Number

11138.105024 MAYO 1001 CON

3466095 1.DOC

U.S. PATENT DOCUMENTS

| Examiner Initials | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pgs, Clms, Lns, Where Relevant Passages/Relevant Figs Appear |
|-------------------|-----------------------|----------------------|----------------------|---|--|--|
| | | Number | Kind Code (if known) | | | |
| DL | AA | 3,627,788 | A | Bouchaudon | 11-27-1968 | |
| | AB | 3,936,440 | A | Nath | 02-03-1976 | |
| DL | AC | 3,981,863 | A | Niswender <i>et al.</i> | 09-21-1976 | |
| | AD | 4,209,614 | A | Bernstein <i>et al.</i> | 06-24-1980 | |
| DL | AE | 4,279,859 | A | Gutcho <i>et al.</i> | 07-21-1981 | |
| | AF | 4,283,342 | A | Yollees | 08-11-1981 | |
| DL | AG | 4,301,140 | A | Frank <i>et al.</i> | 11-17-1981 | |
| | AH | 4,465,775 | A | Houts | 08-14-1984 | |
| DL | AI | 4,612,302 | A | Szabo <i>et al.</i> | 09-16-1986 | |
| | AJ | 4,684,620 | A | Hruby <i>et al.</i> | 08-04-1987 | |
| DL | AK | 4,853,371 | A | Coy <i>et al.</i> | 08-01-1989 | |
| | AL | 5,308,606 | A | Wilson <i>et al.</i> | 05-03-1994 | |
| DL | AM | 5,405,598 | A | Schinazi <i>et al.</i> | 08-11-1995 | |
| | AN | 5,405,839 | A | Toraya <i>et al.</i> | 04-11-1995 | |
| DL | AO | 5,428,023 | A | Russell-Jones <i>et al.</i> | 06-27-1995 | |
| | AP | 5,449,720 | A | Russell-Jones <i>et al.</i> | 09-12-1995 | |
| DL | AQ | 5,462,724 | A | Schinazi <i>et al.</i> | 10-31-1995 | |
| | AR | 5,514,695 | A | Bergeron | 05-07-1996 | |
| DL | AS | 5,548,064 | A | Russell-Jones <i>et al.</i> | 08-20-1996 | |
| | AT | 5,574,018 | A | Habberfield <i>et al.</i> | 11-12-1996 | |
| DL | AU | 5,589,463 | A | Russell-Jones <i>et al.</i> | 12-31-1996 | |
| | AV | 5,599,796 | A | Schinazi <i>et al.</i> | 02-04-1997 | |
| DL | AW | 5,608,060 | A | Axworthy <i>et al.</i> | 03-04-1997 | |
| | AX | 5,739,313 | A | Collins <i>et al.</i> | 04-14-1998 | |
| DL | AY | 5,807,832 | A | Russell-Jones <i>et al.</i> | 09-15-1998 | |
| | AZ | 5,840,880 | A | Morgan, Jr. <i>et al.</i> | 11-24-1998 | |
| DL | AAA | 5,869,465 | A | Morgan, Jr. <i>et al.</i> | 02-09-1999 | |
| | AAB | 5,869,466 | A | Russell-Jones <i>et al.</i> | 02-09-1999 | |
| DL | AAC | 5,872,107 | A | Schinazi <i>et al.</i> | 02-16-1999 | |
| | AAD | 5,877,165 | A | Miura <i>et al.</i> | 03-02-1999 | |
| DL | AAE | 5,936,082 | A | Bauer | 08-10-1999 | |

Examiner
Signature

David Ruckman

Date
Considered

5-3-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|----------------------------|
| Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Complete if Known | |
| | | | | Application Number | 10/777,820 |
| | | | | Filing Date | February 12, 2004 |
| | | | | First Named Inventor | Collins <i>et al.</i> |
| | | | | Group Art Unit | Unassigned |
| | | | | Examiner Name | Unassigned |
| Sheet | 2 | of | 7 | Attorney Docket Number | 11138.105024 MAYO 1001 CON |

3466095 1.DOC

| U.S. PATENT DOCUMENTS | | | | | | |
|------------------------|--------------------------|----------------------|-------------------------|--|--|--|
| Examiner Initials * | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pgs, Clms, Lns, Where Relevant Passages/Relevant Figs Appear |
| | | Number | Kind Code (if known) | | | |
| <i>DL</i> | BA | 6,004,533 | A | Collins <i>et al.</i> | 12-21-1999 | |
| | BB | 6,074,625 | A | Hawthorne <i>et al.</i> | 06-13-1900 | |
| | BC | 6,083,926 | A | Morgan <i>et al.</i> | 07-04-2000 | |
| | BD | 6,083,966 | A | Bergeron, Jr. | 07-04-2000 | |
| | BE | 6,096,290 | A | Collins <i>et al.</i> | 08-01-2000 | |
| | BF | 6,150,341 | A | Russell-Jones, <i>et al.</i> | 11-21-2000 | |
| | BG | 6,180,766 | B1 | Schinazi <i>et al.</i> | 01-30-2001 | |
| | BH | 6,211,355 | B1 | Collins <i>et al.</i> | 04-03-2001 | |
| | BI | 6,262,253 | B1 | Russell-Jones, <i>et al.</i> | 07-17-2001 | |
| | BJ | 6,315,978 | B1 | Grissom <i>et al.</i> | 11-13-01 | |
| | BK | 2002/0042394 | A1 | Hogenkamp <i>et al.</i> | 04-11-2002 | |
| | BL | 2002/0049155 | A1 | Hogenkamp | 04-25-2002 | |
| | BM | 2002/0151525 | A1 | Collins <i>et al.</i> | 10-17-2002 | |
| | BN | 2003/0018009 | A1 | Collins | 01-23-2003 | |
| | BO | 2003/0144198 | A1 | Collins | 07-31-2003 | |
| | BP | 6,613,305 | A1 | Collins <i>et al.</i> | 09-02-2003 | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|--------------------------|-------------------------|-----------|--------------------------------------|---|--|---|
| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Office ² | Number | Kind Code ³ (if known) | | | |
| <i>X</i> | BQ | AU | 04490099 | A1 | Biotech Australia Pty. Ltd. | 01-05-2000 | |
| <i>X</i> | BR | DE | 1,811,518 | | Rhone-Poulenc S.A. (Bouchardon) <i>Chem. Abstr. 71:91866s (1969)</i> | 07-10-1969 | |
| <i>X</i> | BS | EP | 0 005 834 | A1 | E.R. Squibb & Sons, Inc. | 12-12-1979 | |
| <i>X</i> | BT | EP | 0 069 450 | A1 | Technicon Instruments Corp. | 01-12-1983 | |
| <i>X</i> | BU | EP | 0 165 716 | A1 | Micromedic Systems Inc. | 12-27-1985 | |
| <i>X</i> | BV | JP | 58-046027 | A2 | Nippon Meiji Fijitsukusu KK | 03-17-1983 | |
| <i>DL</i> | BW | WO | 89/01475 | A1 | Celltech Ltd.; Parker; Millican | 02-23-1989 | |
| <i>X</i> | BX | WO | 92/09610 | A1 | University of California | 06-11-1992 | |
| <i>X</i> | BY | WO | 92/13571 | A1 | Dow Chemical Company | 08-20-1992 | |
| <i>X</i> | BZ | WO | 94/27613 | A1 | Biotech Australia Pty. Ltd. <i>et al.</i> | 12-08-1994 | |
| <i>X</i> | BAA | WO | 94/27641 | A1 | Biotech Australia Pty. Ltd. <i>et al.</i> | 12-08-1994 | |
| <i>X</i> | BAB | WO | 95/27723 | A1 | Morgan; Wilbur; Pathare | 10-19-1995 | |

| | | | |
|-----------------------|--------------------|--------------------|--------|
| Examiner Signature | <i>David Lyden</i> | Date Considered | 5-3-06 |
|-----------------------|--------------------|--------------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|----------------------------|
| Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Complete if Known | |
| | | | | Application Number | 10/777,820 |
| | | | | Filing Date | February 12, 2004 |
| | | | | First Named Inventor | Collins <i>et al.</i> |
| | | | | Group Art Unit | Unassigned |
| | | | | Examiner Name | Unassigned |
| Sheet | 3 | of | 7 | Attorney Docket Number | 11138.105024 MAYO 1001 CON |

3466095 I.DOC

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----------------------|-------------------------|-----------|-----------------------------------|---|--|---|
| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Office ² | Number | Kind Code ³ (if known) | | | |
| DL | CA | WO | 96/04016 | A1 | Amgen Inc. | 02-15-1996 | |
| DL | CB | WO | 96/27641 | A1 | BioTech Australia | 12-08-1994 | |
| X | CC | WO | 96/31243 | A1 | The DuPont Merck Pharm. Co. | 10-10-1996 | |
| X | CD | WO | 97/14711 | A1 | Receptagen; Univ. Washington | 04-24-1997 | |
| X | CE | WO | 97/18231 | A1 | Regents of Univ. Minnesota | 05-22-1997 | |
| X | CF | WO | 97/33627 | A2 | The DuPont Merck Pharm. Co. | 09-18-1997 | |
| X | CG | WO | 98/08859 | A1 | Univ. Utah Res. Found. | 03-05-1998 | |
| X | CH | WO | 99/65930 | A1 | Biotech Australia Pty. Ltd. | 12-23-1999 | |
| X | CI | WO | 00/45857 | A2 | Schering AG | 08-10-2000 | |
| X | CJ | WO | 00/62808 | A2 | Univ. Minnesota | 10-26-2000 | |
| X | CK | WO | 00/74721 | A1 | Biotech Australia Pty. Ltd. | 12-14-2000 | |
| DL | CL | WO | 01/28592 | A1 | Mayo Found.; U. Minnesota | 04-26-2001 | |
| DL | CM | WO | 01/28595 | A1 | Mayo Found.; U. Minnesota | 04-26-2001 | |
| DL | CN | WO | 01/30967 | A2 | Univ. Utah Res. Found. <i>et al.</i> | 05-03-2001 | |
| DL | CO | WO | 01/92283 | A2 | Mayo Found.; U. Minnesota | 12-06-2001 | |
| DL | CP | WO | 01/92288 | A2 | Collins; Mayo Found.; U. Minn. | 12-06-2001 | |
| DL | CQ | WO | 02/042318 | A2 | Collins; Mayo Found.; U. Minn. | 05-30-2002 | |
| DL | CR | WO | 02/055530 | A2 | Mayo Found.; U. Minnesota | 07-18-2002 | |
| DL | CS | WO | 03/000010 | A2 | Collins | 01-21-2003 | |
| DL | CT | WO | 03/025139 | A2 | Mayo Found. | 03-27-2003 | |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | | | | | |
|---|-----------------------|---|--|--|--|--|-----|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | | | T 6 |
| DL | CU | ALAM, G. <i>et al.</i> , "Boronated compounds for neutron capture therapy," <i>Strahlentherapie und Onkologie</i> , 165(2/3):121-123 (1989). | | | | | |
| DL | CV | ALLEN, R.H., <i>et al.</i> , "Isolation of gastric vitamin B ₁₂ -binding proteins using affinity chromatography," <i>J. Biol. Chem.</i> , 248(10):3660-3669 (May 25, 1973). | | | | | |
| DL | CW | ALLEN, R.H., <i>et al.</i> , "Isolation of vitamin B ₁₂ -binding proteins using affinity chromatography," <i>J. Biol. Chem.</i> , 247(23):7695-7701 (December 10, 1972). | | | | | |
| X | CX | AMAGASAKI, T., <i>et al.</i> , "Expression of transcobalamin II receptors by human leukemia K562 and HL-60 cells," <i>Blood</i> , 76(7):1380-1386, (October 1, 1990). | | | | | |

| | | | |
|--------------------|----------------------|-----------------|--------|
| Examiner Signature | <i>David R. Chan</i> | Date Considered | 5-3-06 |
|--------------------|----------------------|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|-----------------------|------------------------|----------------------------|
| Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Complete if Known | | | |
| | | Application Number | 10/777,820 | | |
| | | Filing Date | February 12, 2004 | | |
| | | First Named Inventor | Collins <i>et al.</i> | | |
| | | Group Art Unit | Unassigned | | |
| | | Examiner Name | Unassigned | | |
| Sheet | 4 | of | 7 | Attorney Docket Number | 11138.105024 MAYO 1001 CON |

3466095 1.DOC

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| <i>DL</i> | DA | ANTON, D.L., <i>et al.</i> , "Carbon-13 nuclear magnetic resonance studies of the monocarboxylic acids of cyanocobalamin. Assignments of the B-, D-, and E-monocarboxylic acids," <i>J. Am. Chem. Soc.</i> , 102(7):2215-2219 (March 26, 1980). | |
| X | DB | ANTON, D.L., <i>et al.</i> , "The synthesis and properties of four spin-labeled analogs of adenosylcobalamin," <i>J. Biol. Chem.</i> 255(10):4507-4510 (May 25, 1980). | |
| X | DC | BEGLEY, J.A., <i>et al.</i> , "Cobalamin metabolism in cultured human chorionic villus cells," <i>J. Cell Physiol.</i> 156(1):43-47 (July 1993). | |
| X | DD | BERNHANER, K., <i>et al.</i> , "Zur Chemie und Biochemie der Corrinoides," <i>Biochem. Z.</i> 344:289-309 (1966). | |
| X | DE | BLOMQUIST, L., <i>et al.</i> , "Uptake of labelled vitamin B ₁₂ and 4-iodophenylalanine in some tumors of mice," <i>Experientia</i> , 25(3):294-296 (March 15, 1969). | |
| X | DF | BREEMAN, W.A., <i>et al.</i> , "Indium-111 labeled DTPA- and DOTA-bombesin analogs for receptor scintigraphy and radiotherapy," in Scientific Papers (June 9, 1999), Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):102P, Abstract no. 413 (May 1999 supplement). | |
| <i>DL</i> | DG | BROAN, C. J., <i>et al.</i> , "Synthesis and complexation behaviour of an effective octadentate complexone 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis[methylene(methylphosphinic acid)]," <i>J. Chem. Soc. Chem. Comm.</i> , 23:1739-1741 (1990). | |
| X | DH | COLLINS, D.A., <i>et al.</i> , "Transcobalamin II receptor imaging via radiolabeled diethylene-triaminepentaacetate cobalamin analogs," <i>J. Nucl. Med.</i> , 38(5):717-723 (May 1997). | |
| X | DI | COLLINS, D.A., <i>et al.</i> , "Tumor imaging via indium 111-labeled DTPA-adenosylcobalamin," <i>Mayo Clin. Proc.</i> , 74(7):687-691 (July 1999). | |
| X | DJ | COOPER, B.A., <i>et al.</i> , "Selective uptake of specifically bound cobalt-58 vitamin B ₁₂ by human and mouse tumour cells," <i>Nature</i> , 191, 393-395 (July 1961). | |
| X | DK | De JONG, M., <i>et al.</i> , "Radionuclide therapy using radiolabeled somatostatin analogs in tumor-bearing rats," in Scientific Papers (June 9, 1999), Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):102, Abstract no. 414 (May 1999 supplement). | |
| <i>DL</i> | DL | ELLENBOGEN, L., "Absorption and transport of cobalamin: Intrinsic factor and the transcobalamins," <i>Cobalamin: Biochemistry and Pathophysiology</i> , Babior, Ed., Wiley, New York (1975), Chapter 5. | |
| <i>DL</i> | DM | FAIRCHILD, R.G., <i>et al.</i> , "Current status of 10-B-neutron capture therapy: enhancement of tumor dose via beam filtration and dose rate, and the effects of these parameters on minimum boron content: A theoretical evaluation," <i>Int. J. Radiation Oncology, Biology, Physics</i> , 11(4):831-840 (April 1985). | |

| | | | |
|--------------------|-----------------------|-----------------|--------|
| Examiner Signature | <i>David L. Lukan</i> | Date Considered | 5-3-06 |
|--------------------|-----------------------|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0631-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|-----------------------|------------------------|----------------------------|
| Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Complete if Known | | | |
| | | Application Number | 10/777,820 | | |
| | | Filing Date | February 12, 2004 | | |
| | | First Named Inventor | Collins <i>et al.</i> | | |
| | | Group Art Unit | Unassigned | | |
| | | Examiner Name | Unassigned | | |
| Sheet | 5 | of | 7 | Attorney Docket Number | 11138.105024 MAYO 1001 CON |

3466095 I.DOC

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| X | EA | RINKLER, A.E., <i>et al.</i> , "Nature of the relationship between vitamin B12 binding and cell uptake," <i>Arch. Biochem. Biophys.</i> , 120(1):79-85 (April 1967). | |
| X | EB | FLODH, H., <i>et al.</i> , "Accumulation of labelled vitamin B12 in some transplanted tumours," <i>Int. J. Cancer</i> , 3(5):694-699 (September 15, 1968). | |
| DE | EC | GABEL, D., "Tumor-Seeking Compounds for Boron Neutron Capture Therapy: Synthesis and Biodistribution," <i>Clinical Aspects of Neutron Capture Therapy</i> , Ralph G. Fairchild <i>et al.</i> , eds.; Plenum Press, New York, (undated), 233-241. | |
| DE | ED | GABEL, D., <i>et al.</i> , "Monte Carlo simulation of the biological effect of the ¹⁰ B(n,α) ⁷ Li reaction in cells and tissue and its implication for boron neutron capture therapy," <i>Radiation Research</i> , 111:14-25 (1987). | |
| X | EE | HALL, C.A., <i>et al.</i> , "Cyclic activity of the receptors of cobalamin bound to transcobalamin-H," <i>J. Cell. Physiol.</i> , 133(1):187-191 (October 1987). | |
| DE | EF | HATANAKA, H., "A revised boron-neutron capture therapy for malignant brain tumors," <i>Journal of Neurology</i> , 209:81-94 (1975). | |
| X | EG | HATANAKA, H., <i>et al.</i> , "Chapter XXV: Clinical Experience of Boron-Neutron Capture Therapy for Gliomas -- A Comparison with Conventional Chemo-Immuno-Radiotherapy," pp. 349-379. (undated) | |
| DE | EH | HAWTHORNE, M.F., <i>et al.</i> , "Preparation of tumor-specific boron compounds. 1. <i>In vitro</i> studies using boron-labeled antibodies and elemental boron as neutron target(s)," <i>Journal of Medicinal Chemistry</i> , 15(5):449-452 (1992). | |
| DE | EI | HOGENKAMP, H. <i>et al.</i> , "Synthesis and Characterization of nido-Carborane-Cobalamin Conjugates," <i>Nucl. Med. & Biol.</i> , 27:89-92 (2000). | |
| X | EJ | HOGENKAMP, H.P.C., Chemical synthesis and properties of analogs of adenosylcobalamin, <i>Biochemistry</i> , 13(13):2736-2740 (1974). | |
| DE | EK | HOGENKAMP, H.P.C., <i>et al.</i> , "Carbon-13 nuclear magnetic resonance studies of adenosylcobalamin and alkylcorrinoids, selectively enriched with carbon-13," <i>Biochemistry</i> , 14(16):3707-3714 (1975). | |
| DE | EL | ICHIHASHI, M., <i>et al.</i> , "Specific killing effect of ¹⁰ B ₁ -para-boronophenylalanine in thermal neutron capture therapy of malignant melanoma: <i>In vitro</i> radiobiological evaluation," <i>The Journal of Investigative Dermatology</i> , 78(3):215-218 (1982). | |
| DE | EM | JACOBSEN, D.W., <i>et al.</i> , "Rapid purification of cobalamin-binding proteins using immobilized aminopropylcobalamin," <i>Anal. Biochem.</i> , 113:164-171 (1981). | |
| DE | EN | KIKUGAWA, K., <i>et al.</i> , "Direct halogenation of sugar moiety of nucleosides," <i>Tetrahedron Letters</i> , 1971(2):87-90 (1971). | |
| X | EO | KAHL, S.B., <i>et al.</i> , "Chemical and biological studies on boronated tetraphenyl porphyrins," <i>Boron Chemistry</i> , 61-67 | |

| | | | |
|--------------------|------------------------|-----------------|--------|
| Examiner Signature | <i>David R. Hanson</i> | Date Considered | 5-3-06 |
|--------------------|------------------------|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|----------------------------|
| Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Complete if Known | |
| | | | | Application Number | 10/777,820 |
| | | | | Filing Date | February 12, 2004 |
| | | | | First Named Inventor | Collins <i>et al.</i> |
| | | | | Group Art Unit | Unassigned |
| | | | | Examiner Name | Unassigned |
| Sheet | 6 | of | 7 | Attorney Docket Number | 11138.105024 MAYO 1001 CON |

3466095 1.DOC

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| | FA | LASTER, B.H., <i>et al.</i> , "Biological efficacy of a boronated porphyrin as measured in cell culture," <i>Strahlentherapie und Onkologie</i> , 165(2/3):203-205 (1989). | |
| X | FB | LINDEMANS, J., <i>et al.</i> , "Uptake of transcobalamin II-bound cobalamin by HL-60 cells: effects of differentiation induction," <i>Experimental Cell Research</i> , 184(2):449-460 (Oct. 1989). | |
| X | FC | LUO, S.Z., "Studies on bone tumor therapeutic radiopharmaceuticals.IV. Investigation of the structure-activity relationships (SARS) of ¹⁵³ Sm-aminocarboxylate complexes," in Poster Sessions, Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):316P, Abstract no. 1386 (May 1999 supplement). | |
| | FD | McBRIDE, W.J., "A general method for the introduction of metal binding ligands onto the side chains of peptides during peptide synthesis," in Scientific Papers (June 9, 1999), Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):124P, Abstract no. 500 (May 1999 supplement). | |
| | FE | MEASE, R.C., <i>et al.</i> , "Indium-111 CDTA-(aminostyryl)pyridiniumum (di-X-asp) dyes: synthesis, canine and human leukocyte labeling, and serum stability," in Poster Sessions, Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):318P, Abstract no. 1396 (May 1999 supplement). | |
| | FF | MISHIMA, Y., <i>et al.</i> , "Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking B-compound," <i>Lancet</i> , 2(8659):388-389 (August 12, 1989). | |
| X | FG | MISHIMA, Y., <i>et al.</i> , "First human clinical trial of melanoma neutron capture. Diagnosis and therapy," <i>Strahlentherapie und Onkologie</i> , 165(2/3):251-254 (1989). | |
| X | FH | MOMEN, A., <i>et al.</i> , "Impact of high resolution bone spect imaging of the thoracolumbar spine on patient management in oncology," in Scientific Papers (June 9, 1999), Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):124P, Abstract no. 500 (May 1999 supplement). | |
| | FI | NAKAGAWA, T., <i>et al.</i> , "Syntheses of chlorpromazine undecahydrododecaborate and nonahydrodecaborate -- promising agents for neutron capture therapy of malignant melanoma," <i>Chem. Pharm. Bull. (Tokyo)</i> , 24(4):778-781 (1976) [UDC 547.869.2.04; 547.244.04] | |
| | FJ | NEXO, E., "Cobalamin-binding proteins," Chapter 30 in <i>Vitamin B₁₂ and B₁₂ Proteins</i> , B. Krantler <i>et al.</i> , Eds., Wiley & Sons, New York (1997), pp. 461-475. | |
| | FK | NORENBERG, J.P., "[²¹³ Bi-DOTA ⁰ , Tyr ¹]octreotide (²¹³ Bi-DOTATOC) in peptide receptor radionuclide therapy (PRRT)," in Scientific Papers (June 9, 1999), Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):103, Abstract no. 415 (May 1999 supplement). | |

| | | | |
|--------------------|--|-----------------|--------|
| Examiner Signature | | Date Considered | 5-3-06 |
|--------------------|--|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|-----------------------|------------------------|----------------------------|
| Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Complete if Known | | | |
| | | Application Number | 10/777,820 | | |
| | | Filing Date | February 12, 2004 | | |
| | | First Named Inventor | Collins <i>et al.</i> | | |
| | | Group Art Unit | Unassigned | | |
| | | Examiner Name | Unassigned | | |
| Sheet | 7 | of | 7 | Attorney Docket Number | 11138.105024 MAYO 1001 CON |

3466095 1.DOC

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| | GA | ORDER, S.E., <i>et al.</i> , "Use of isotopic immunoglobulin in therapy," <i>Cancer Res.</i> , 40:3001-3007 (August 1980) | |
| | GB | PISAL, S.S., <i>et al.</i> , "Formulation of nasal gels of Vitamin B12-1: Effect of additives on thermodynamic properties of pluronic PF-127 gels," <i>Indian J. Pharm. Sci.</i> (May-June 2002), accessed November 12, 2002, at www.indianpharma.org/may-june2002/fnasalgels.html . | |
| | GC | PRIMUS, F.J., <i>et al.</i> , "Bispecific antibody mediated targeting of nido-carboranes to human colon carcinoma cells," <i>Bioconjugate Chemistry</i> , 7:532-535 (1996). | |
| | GD | RAO, P.S., <i>et al.</i> , "TC-99M labeled peptide for imaging infection," in Poster Sessions, Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):319P, Abstract no. 1398 (May 1999 supplement). | |
| | GE | RAPPAZZO, M.E., <i>et al.</i> , "Transport function of transcobalamin H," <i>J. Clin. Invest.</i> , 51(7), 1915-1918 (July 1972). | |
| | GF | ROE, D.G., <i>et al.</i> , "Combinatorially designed technetium radiopharmaceuticals (CDTR TM)," in Scientific Papers, Proc. of the 46 th Annual Meeting of the Society of Nuclear Medicine (Los Angeles, California, June 6-10, 1999), <i>J. Nuc. Med.</i> , 40(5):123P, Abstract No. 499 (May 1999 supplement). | |
| | GG | RUSER, G., <i>et al.</i> , "Synthesis and evaluation of two new bidentate carboxymethylated tetrazamacrocylic chelating agents for protein labeling with Indium-111," <i>Bioconj. Chem.</i> , 1:345-349 (1990). | |
| | GH | SATTELBERGER, A.R., <i>et al.</i> , "Nuclear medicine finds the right chemistry," <i>Nature Biotechnology</i> , 849-850, Vol. 17, September 1999. | |
| | GI | SMELTZER, C.C., <i>et al.</i> , "Synthesis and characterization of fluorescent cobalamin (CobalaFluor) derivatives for imaging," <i>Organic Letters</i> , 3(6):799-801 (2001). | |
| | GJ | TORAYA, T., <i>et al.</i> , "Preparation, properties and biological activities of succinyl derivatives of vitamin B ₁₂ ," <i>Bioinorg. Chem.</i> , 4:245-255 (1975). | |
| | GK | WILBUR, D.S., <i>et al.</i> , "Evaluation of Biotin-Dye Conjugates for Use in an HPLC Assay to Assess Relative Binding of Biotin Derivatives with Avidin and Streptavidin," <i>Bioconjugate Chem.</i> , 11(4), 584-598 (July-August 2000). | |
| | GL | WILBUR, D.S., <i>et al.</i> , "Biotin Reagents for Antibody Pretargeting. 4. Selection of Biotin Conjugates for in Vivo Application Based on Their Dissociation Rate from Avidin and Streptavidin," <i>Bioconjugate Chem.</i> , 11(4), 569-583 (July-August 2000). | |
| | GM | WU, C., VIRZI, F., and HNATOWICH, D.J., "Investigations of N-linked macrocycles for ¹¹¹ In and ⁹⁰ Y labeling of proteins," <i>Nucl. Med. Biol.</i> , 19(2):239-244 (1992) [<i>Int. J. Radiat. Appl. Instrum. Part B</i>]. | |

| | | | |
|--------------------|--|-----------------|--------|
| Examiner Signature | | Date Considered | 5-3-06 |
|--------------------|--|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.